ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2009;88:253-257. doi:10.1016/j.athoracsur.2009.01.058
© 2009 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Loes D. Sauren
Gil Bolotin
Frederik H. van der Veen
Jos G. Maessen
Right arrow Permission Requests
Google Scholar
Right arrow Articles by Sauren, L. D.
Right arrow Articles by Maessen, J. G.
PubMed
Right arrow Articles by Sauren, L. D.
Right arrow Articles by Maessen, J. G.
Related Collections
Right arrow Extracorporeal circulation

New Technology

The EmBlocker: Efficiency of a New Ultrasonic Embolic Protection Device Adjunctive to Heart Valve Surgery

Loes D. Sauren, Msc*, Mark la Meir, MD, Gil Bolotin, MD, PhD, Frederik H. van der Veen, PhD, John H. Heijmans, MD, PhD, Werner H. Mess, MD, PhD, Jos G. Maessen, MD, PhD

Departments of Cardiothoracic Surgery and Clinical Neurophysiology, Academic Hospital Maastricht, Maastricht, the Netherlands

Accepted for publication January 22, 2009.

* Address correspondence to Dr Sauren, Department of Cardiothoracic Surgery, Academic Hospital Maastricht, P. Debyelaan 25, Maastricht, 6229HX, the Netherlands (Email: l.sauren{at}ctc.unimaas.nl).

Purpose: Perioperative cerebral microemboli in cardiac surgery are associated with postoperative neurologic complications. The EmBlocker (Neurosonix Ltd, Rehovot, Israel), a newly developed device should be positioned against the ascending aorta, and it produces an ultrasonic force expected to divert microemboli away from the cerebral vasculature and reduce cerebral emboli.

Description: Twenty-one consecutive patients, undergoing a valve procedure, were enrolled into this nonrandomized pilot study. The EmBlocker (Neurosonix Ltd) was positioned in 11 consecutive patients and activated for 1 minute (1.5 W/cm2) during seven selected aortic manipulations and for 10 minutes (0.5 W/cm2) intermittently after cross-clamp removal. Transcranial Doppler-based quantification of microembolic signals was performed in all patients.

Evaluation: The use of the EmBlocker showed a significant overall reduction of the cerebral microembolic signals of 53%.

Conclusions: The use of the EmBlocker during valve surgeries is associated with a reduction of perioperative cerebral microembolic signals. This new technology holds the potential to lower the risk of postoperative neurologic complications.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The Society of Thoracic Surgeons.